$1.95
4.84% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US44934S2068
Symbol
ICAD

iCAD, Inc. Stock price

$1.95
+0.18 10.17% 1M
+0.65 50.00% 6M
+0.18 10.17% YTD
+0.07 3.72% 1Y
-5.15 72.54% 3Y
-5.81 74.87% 5Y
-7.25 78.80% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.09 4.84%
ISIN
US44934S2068
Symbol
ICAD
Sector

Key metrics

Market capitalization $51.75m
Enterprise Value $33.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.76
P/S ratio (TTM) P/S ratio 2.73
P/B ratio (TTM) P/B ratio 1.75
Revenue growth (TTM) Revenue growth -14.70%
Revenue (TTM) Revenue $18.94m
EBIT (operating result TTM) EBIT $-6.12m
Free Cash Flow (TTM) Free Cash Flow $-4.66m
Cash position $18.79m
EPS (TTM) EPS $-0.13
P/E forward negative
P/S forward 2.77
EV/Sales forward 1.78
Short interest 0.96%
Show more

Is iCAD, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

iCAD, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a iCAD, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a iCAD, Inc. forecast:

Buy
100%

Financial data from iCAD, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
19 19
15% 15%
100%
- Direct Costs 2.90 2.90
50% 50%
15%
16 16
2% 2%
85%
- Selling and Administrative Expenses 15 15
21% 21%
80%
- Research and Development Expense 6.45 6.45
1% 1%
34%
-5.59 -5.59
40% 40%
-30%
- Depreciation and Amortization 0.53 0.53
49% 49%
3%
EBIT (Operating Income) EBIT -6.12 -6.12
41% 41%
-32%
Net Profit -3.40 -3.40
66% 66%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about iCAD, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

iCAD, Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment
Neutral
GlobeNewsWire
24 days ago
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
Neutral
GlobeNewsWire
about one month ago
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
More iCAD, Inc. News

Company Profile

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Head office United States
CEO Dana Brown
Employees 69
Founded 1984
Website www.icadmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today